As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people ...
Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. MyoKardia, a biotech BMS bought in 2020, was working with Fulcrum to find cardiomyopathy targets but recently decided to end the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results